Choose your font:
 Arimo
 Merriweather
 Mukta Malar
 Open Sans Condensed
 Rokkitt
 Source Sans Pro
 Login


 English 
 Français 
 Português 

[Valid RSS] RSS
bar

Database - Alliance francophone pour l'accouchement respecté (AFAR)

Description of this bibliographical database (AFAR website)
Currently 3046 records
YouTube channel (tutorial)

https://afar.info/id=2829

Created on : 26 Nov 2017
Modified on : 26 Nov 2017

 Modify this record
Do not follow this link unless you know an editor’s password!


Share: Facebook logo   Tweeter logo   Hard

Bibliographical entry (without author) :

Cardiotocographic abnormalities associated with misoprostol and dinoprostone cervical ripening and labor induction - European Journal of Obstetrics Gynecology and Reproductive Biology - Vol. 156, 2 - p.144-148

Author(s) :

Pevzner, L.; Alfirevic, Z.; Powers, B.L.; Wing, D.A.

Year of publication :

2011

URL(s) :

https://www.scopus.com/inward/record.uri?eid=2-s2.…
https://doi.org/10.1016/j.ejogrb.2011.01.015

Résumé (français)  :

Abstract (English)  :

Objective: To characterize the incidence and timing of cardiotocographic (CTG) abnormalities associated with misoprostol and dinoprostone vaginal inserts during labor induction. Study design: This was a secondary analysis of data collected during the misoprostol vaginal insert (MVI) trial, a multi-site, double-masked, randomized trial of women requiring cervical ripening before induction of labor. The timing, incidence and clinical outcomes associated with CTG abnormalities were analyzed among three study groups. Results: 1308 subjects were randomized to receive dinoprostone pessary, misoprostol 50 mcg (MVI 50) or 100 mcg (MVI 100) vaginal insert. 6.8% of MVI 50-treated women had a uterine contractile abnormality (hyperstimulation, hypertonus and/or tachysystole) while the study drug was in situ, compared to 17.4% with dinoprostone insert (p < 0.001) and 17.3% with MVI 100 (p < 0.001). There was no significant difference in incidence of fetal heart rate (FHR) abnormalities that occurred with the study drug - 11.2% with dinoprostone, compared to 9.9% with MVI 50 and 10.7% with MVI 100. Cardiotocographic (CTG) abnormalities while the study drug was in situ occurred later in women treated with MVI 50 (7.5 h [6.2-9.8]) compared to dinoprostone (5.5 h [4.2-6.6], p = 0.003) and MVI 100 (7.0 h [5.7-7.9], p = 0.13). Eight participants in MVI 50 group underwent cesarean section secondary to a CTG event that was initially noted with the study drug in situ, compared to eight dinoprostone-treated participants and 16 in the MVI 100 group, but these differences were not statistically significant. Conclusion: Cardiotocographic abnormalities were less frequent and occurred after longer exposure with MVI 50 than MVI 100 or dinoprostone. Clinical outcomes were similar among the groups. © 2011 Elsevier Ireland Ltd. All rights reserved.

Sumário (português)  :

Comments :

Argument (français) :

Argument (English):

Argumento (português):

Keywords :

➡ induction of labor ; ripening of cervix ; misoprostol (Cytotec)

Author of this record :

Import 26/11/2017 — 26 Nov 2017
➡ latest update : Bernard Bel — 26 Nov 2017

Discussion (display only in English)
 
➡ Only identified users



 I have read the guidelines of discussions and I accept all terms (read guidelines)

barre

New expert query --- New simple query

Creating new record --- Importing records

User management --- Dump database --- Contact

bar

This database is managed by Alliance francophone pour l'accouchement respecté (AFAR, https://afar.info)
affiliated with Collectif interassociatif autour de la naissance (CIANE, https://ciane.net).
It is fed by the voluntary contributions of persons interested in the sharing of scientific data.
If you agree with this project, you can support us in several ways:
(1) contributing to this database if you have a minimum training in documentation
(2) or financially supporting AFAR (see below)
(3) or joining the AFAR (or another society affiliated with CIANE).
Sign in or create an account to follow changes or become an editor.
Contact afar.association(arobase)gmail.com for more information.

Valid CSS! Valid HTML!
Donating to AFAR (click “Faire un don”) will help us to maintain and develop sites and public
databases towards the support of parents and caregivers’ informed decisions with respect to childbirth